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Engineered trivalent immunogen adjuvanted with a STING
agonist confers protection against Trypanosoma cruzi infection
Andrés Sanchez Alberti 1,2,3, Augusto E. Bivona1,2, Natacha Cerny1,2, Kai Schulze3, Sebastian Weißmann3, Thomas Ebensen3,
Celina Morales4, Angel M. Padilla5, Silvia I. Cazorla1,2, Rick L. Tarleton5, Carlos A. Guzmán3 and Emilio L. Malchiodi 1,2
The parasite Trypanosoma cruzi is the causative agent of Chagas disease, a potentially life-threatening infection that represents a
major health problem in Latin America. Several characteristics of this protozoan contribute to the lack of an effective vaccine,
among them: its silent invasion mechanism, T. cruzi antigen redundancy and immunodominance without protection. Taking into
account these issues, we engineered Traspain, a chimeric antigen tailored to present a multivalent display of domains from key
parasitic molecules, combined with stimulation of the STING pathway by c-di-AMP as a novel prophylactic strategy. This formulation
proved to be effective for the priming of functional humoral responses and pathogen-specific CD8+ and CD4+ T cells, compatible
with a Th1/Th17 bias. Interestingly, vaccine effectiveness assessed across the course of infection, showed a reduction in parasite
load and chronic inflammation in different proof of concept assays. In conclusion, this approach represents a promising tool against
parasitic chronic infections.
npj Vaccines  (2017) 2:9 ; doi:10.1038/s41541-017-0010-z
INTRODUCTION
Trypanosoma cruzi is the etiological agent of Chagas disease, the
world’s leading cause of infectious myocarditis. It is recognized by
WHO as a neglected tropical disease in Latin America, where one-
sixth of the population is at risk of contracting the infection.1
The infection is a complex zoonosis transmitted by several
hematophagous Triatomine species. Despite the potent immune
response the parasite triggers in the mammalian host, T. cruzi is
able to persist, establishing a chronic infection. One hundred years
following its discovery, there are still no effective vaccines or drugs
to prevent or treat the chronic phase of the infection.
As T. cruzi spends most of its time in mammals as amastigote
form replicating in the cytosol of host cells, cell-mediated
immunity is essential for controlling the parasite.2 However, it
has been shown that the cytotoxic T lymphocyte (CTL) response
developed is restricted to a few epitopes of the Transialidase (TS)
superfamily,3 giving rise to the question of immunodominance as
an immune evasion mechanism.4 The redundancy of some T. cruzi
antigens and the parasite silent invasion mechanism contribute to
the lack of detection of infected cells during the first moment of
entrance and represent a challenge in the design of anti-T. cruzi
prophylactic vaccines. This scenario allows speculation about
whether a chimeric immunogen could broaden the immune
response triggered by vaccination and achieve better protection
levels. To test this hypothesis, we engineered Traspain, a structure-
based chimeric antigen, relying on several properties of three
regions of T. cruzi proteins: (1) immunogenicity, (2) presence of
reported and predicted major histocompatibility complex class I
binding peptides, (3) protection capacity, (4) expression profile,
and (5) structural signature. Thus, we selected the N-terminal
domain of Cruzipain (Cz)—the major cistein protease—, the central
region of amastigote surface protein 2 (ASP2)—an antigen
expressed exclusively during the intracellular stage—, and an
inactive transialidase (iTS)—a major antigen and virulence factor—,
to generate a chimeric antigen presenting a multivalent display of
key parasitic molecules.
Subunit vaccines need not only a good immunogen but also
the right adjuvant. In search of novel components that can
enhance cell-mediated immunity, we employed 3′5′-c-di-AMP (c-
di-AMP), a cyclic di nucleotide (CDN), in vaccination protocols by
the intranasal route. CDNs are STING agonists that activate IRF3,
NF-kB, and STAT6, inducing type I IFN and pro-inflammatory
cytokines;5, 6 originally described as bacterial second messengers
associated with different metabolic process. Mammalian cells have
also an eukaryotic counterpart, 2′5 ′-c-GAMP, as part of their DNA
sensing machinery.7 These small molecules have been recently
introduced as adjuvants.8 Here, we show how tailored antigen
combined with this novel adjuvant represents a promising
strategy for vaccines against parasitic infections.
RESULTS
Construction, expression and characterization of Traspain
Traspain was designed containing the Nt-Cz-domain, an α-helix
linker from iTS and the central region of ASP2 (Fig. 1a). It was
expressed in E. coli BL21 (DE3) and the immunochemical identity
was determined by Western blot where Traspain was recognized
by polyclonal antibodies specific for the main domains (Fig. 1b).
Received: 28 September 2016 Revised: 1 February 2017 Accepted: 10 February 2017
1Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Cátedra de Inmunología and Instituto de Estudios de la Inmunidad Humoral (IDEHU), UBA-CONICET, Buenos
Aires, Argentina; 2Universidad de Buenos Aires, Facultad de Medicina, Departamento de Microbiología, Parasitología e Inmunología and Instituto de Microbiología y Parasitología
Médica (IMPaM), UBA-CONICET, Buenos Aires, Argentina; 3Department of Vaccinology and Applied Microbiology, Helmholtz Center for Infection Research, Braunschweig,
Germany; 4Universidad de Buenos Aires, Facultad de Medicina, Departamento de Patología, Instituto de Fisiopatología Cardiovascular, Buenos Aires, Argentina and 5Center for
Tropical and Emerging Global Diseases, Athens, GA, USA
Correspondence: Emilio L. Malchiodi (emalchio@ffyb.uba.ar)
www.nature.com/npjvaccines
Published in partnership with the Sealy Center for Vaccine Development
Immunization with Traspain+c-di-AMP achieved an equal level of
priming at both humoral and cellular levels
As Traspain antigen contains domains from different protein
families of the parasite, we decided to test whether any
interference was developed between the main regions of the
construction when the protein was administered to C3H mice in
the presence of a STING agonist as adjuvant.
Antibodies raised against Traspain were able to recognize Nt-Cz,
ASP2 and GELRIIKSV peptide from the α-helix linker in an indirect
ELISA-assay (Fig. 1c). Remarkably, a similar level of Abs was
detected against both Nt-Cz and ASP2, indicating absence of
interference and inmunodominance at the humoral level.
GELRIIKSV-specific IgG were detected in mice vaccinated with
the chimeric molecule but not in controls (c-di-AMP) nor in Nt-Cz
+ASP2 vaccinated mice that lack this motive. The lower titer of this
specificity was expected considering the 9-mer peptidic nature of
the coating molecule.
Considering the report of ASP2 immunodominant
T cell epitopes in natural infection,9 we analyzed the performance
of Traspain+c-di-AMP to prime cell-mediated immune responses
against each domain. No differences were detected in the
proliferation levels of the Nt-Cz and ASP2-specific subpopulations,
PI: 7.17 ± 2.44 and 8.02 ± 1.03, respectively; representing nearly
half of the whole response (PI: 18.2 ± 5.78) upon restimulation
with Traspain (Fig. 1d).
Antibodies elicited by Traspain+c-di-AMP show neutralization
capacity
T. cruzi-specific antibodies have been shown to be beneficial for
the development of functional parasite-specific CD8+ T cells upon
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Fig. 1 Characterization of Traspain as a chimeric immunogen. Schematic representation of Traspain. Arrows point at CD8+ T cell epitopes
included in the design with its respective mouse MHC-I haplotype (a). Immunochemical identity by Western blot. Domain-specific polyclonal
antibodies (pAb) were used as primary antibody. SDS-PAGE gels were loaded as follows, lines: 1-MWM, 2-Traspain, 3-Nt-Cz (left) or ASP2 (right),
arrows point at Traspain band (b). Specific antibodies response. Titers were determined by ELISA in serum samples from mice vaccinated with
either Traspain or antigen combination plus c-di-AMP at 15 days post vaccination. Plates were coated with Traspain, Nt-Cz, ASP2 (left) or
GELRIIKSV α-linker-peptide (right). * p< 0.05, one-way ANOVA Kruskal-Wallis test + Dunn’s multiple comparisons test (c). Proliferative response
in vaccinated mice 30 days after the last dose. Spleen cells were re-stimulated with 10 µg/ml of the indicated protein. Results are expressed as
proliferation index (PI), n= 6 mice per group, **p< 0.01, 2-way-ANOVA + Tukey’s multiple comparisons test (d). Neutralization assay of pAb
generated upon vaccination. n= 5–6 per group, **p< 0.01, one-way-ANOVA Kruskal-Wallis test + Dunn’s multiple comparisons test (e). Results
are expressed as mean± SEM and are representative of at least three independent experiments
Chimera and c-di-AMP protect against T. cruzi
A Sanchez Alberti et al
2
npj Vaccines (2017)  9 Published in partnership with the Sealy Center for Vaccine Development
challenge.10 Traspain-specific-antibodies proved to be functional
since incubation of trypomastigotes of Tulahuen strain with serum
of vaccinated mice significantly decrease in vitro invasion of non-
phagocytic and Raw-cells (Fig. 1e). Interestingly, the percentage of
inhibition was slightly higher in Traspain+c-di-AMP group
compare with sera from mice vaccinated with the main antigens
combined.
Immunization with Traspain+c-di-AMP primes a balanced immune
response associated with a Th1/Th17 profile
Considering that the cellular immune response is essential to
control intracellular pathogens like T. cruzi, we evaluated the
ability of different vaccine candidates to elicit cell-mediated
immunity. First, the proliferative potential was evaluated in vitro
upon restimulation with Traspain. All vaccinated mice displayed a
strong proliferative response against Traspain in a dose depen-
dent manner (Fig. 2a).
The presence of Traspain, ASP2 and Nt-Cz-specific IFN-γ, IL-17,
IL-2, and IL-4 secreting cells was assessed by ELISpot assay
(Fig. 2b, c). Spleen cells from neither c-di-AMP nor Traspain
groups secreted cytokines upon restimulation. However, all
antigen+c-di-AMP-immunized groups secreted cytokines upon
antigen reencounter with a profile compatible with a Th1/Th17
bias. Thus, splenocytes from mice immunized with Traspain+c-
di-AMP predominantly secreted IFN-γ (11-fold increment over
control), IL-2 (15-fold) and IL-17 (340-fold) upon ex-vivo restimula-
tion with Traspain. In addition, we detected low levels of IL-4-
specific secreting cells; being the ratio IFN-γ(Traspain+c-di-AMP−c-di-AMP)/
IL-4(Traspain+c-di-AMP−c-di-AMP) ≈ 17. Although the magnitude of IFN-γ
and IL-2-secreting cells in Nt-Cz+ASP2+c-di-AMP group was
similar to that of Traspain+c-di-AMP, the levels of IL-17 secreting
cells were significantly less incremented. When we compared the
groups that received antigens alone, an analogous scenario was
observed for the ASP2+c-di-AMP group being the Nt-Cz+c-di-AMP
group more similar in magnitude to Traspain+c-di-AMP.
The numbers of IL-2-Traspain-specific secreting cells were
comparable in all antigen+c-di-AMP immunized groups a fact
that correlates with the similar level of proliferation observed.
Furthermore, to confirm the absence of immunodominance
towards the domains of the chimeric molecule, we also performed
restimulation of spleen cells with the main antigens (Fig. 2c).
Interestingly, Traspain immunized splenocytes respond to ASP2
and Nt-Cz in a similar fashion, revealing a balanced response to
both of them.
Antigen-specific CD4+ T cells upregulate CD154 and secrete IFN-γ
and TNF-α
In order to characterize the functionality of the CD3+CD4+ T cells,
we performed FACS analysis of spleen cells from vaccinated and
control mice. As shown in Fig. 3a, CD4+ T cells transiently
upregulated CD154 upon restimulation with Traspain in all
immunized mice. Moreover, most cells positive for this marker
were also cytokine-producing cells compared with controls, as
shown in Fig. 3b–e. In consistence with the results obtained in the
ELISPOT assay, the group that received Nt-Cz+ASP2+c-di-AMP
presented an immune response not as robust as Traspain+c-di-
AMP, showing lower levels of activated CD154+ cells and nearly
half of the percentage of triple positive CD4+CD154+TNF-α+IFN-γ
+ T cells upon antigen recall. Activation of CD4 T cells was similar
for the antigen alone+c-di-AMP groups although citoquine
positive cells were higher in the Nt-Cz+c-di-AMP group after
protein restimulation.
Altogether, these results highlight the ability of the formulation
to generate high quality multifunctional CD4+ T cells that may
help not only during the priming of CD8+ T cells, but also to
activate infected macrophages during T. cruzi infection.
Mucosal administration of Traspain+c-di-AMP is able to prime
systemic parasite-specific CD8+ T cells
Due to the key role of cytotoxic T cells in controlling parasite load
during the acute phase of infection, we analyzed the ability of c-
di-AMP to prime antigen-specific CD8+ T cells as a correlate of
protection. Immunization with candidates plus c-di-AMP was able
to prime parasite-specific CD8+ T cells for the immunodominant
epitope of ASP2 as we determined by H2Kk-TEWETGQI multimer
staining albeit levels tend to be lower in the Nt-Cz+ASP2+c-
di-AMP group. As expected, we did not detect an expansion of
CD8+ T cells with this specificity in Nt-Cz+c-di-AMP vaccinated
animals (Fig. 4a, b). Interestingly, these cells were also recirculating
as we detected them in blood in the Traspain+c-di-AMP group
(Fig. 4c, d).
Additionally, the functionality of CD8+ T cells was determined
by its capacity to degranulate ex-vivo upon re-encounter with
Traspain. We observed a higher frequency of CD8+ T cells
expressing CD107α in immunized groups compared with the c-
di-AMP control (Fig. 4e, f). Moreover, Traspain+c-di-AMP vacci-
nated mice showed the best cytotoxic potential as detected by
the upregulation of this marker.
Re-expansion capacity and functionality of vaccine-specific CD8+ T
cell response upon T. cruzi infection
With the aim of determining the impact of T. cruzi infection on
pre-existing cell-mediated immunity, the percentage of H2Kb-
VNHRFTLV tetramer+ CD8+ T cells from vaccinated C57BL/6 mice
was evaluated. Similar to what we found for the H2Kk haplotype,
Traspain+c-di-AMP-vaccinated mice were able to prime pathogen-
specific CD8+ T cells from the ASP2 region of the chimeric antigen
on the H2Kb background. These cells were further expanded after
T. cruzi CL infection, where we observed a two-fold increase in the
frequency of H2Kb tetramer positive cells compared with both
infected non-vaccinated and vaccinated not infected mice (Fig. 5a,
b). In addition, the presence of antigen-specific CD8+ T cells did
not affect the ability of the immune system to recognize and
prime CD8+ cells against an unrelated parasite peptide as Tskb20
from TS (Fig. 5a I).
To compare functional aspects of the CTL response, we
analyzed the lysis of peptide-pulsed splenocytes in an in vivo
CTL assay in traspain-vaccinated C3H mice before and after T. cruzi
challenge (Fig. 5c). In accordance with the CD107α staining,
Traspain+c-di-AMP mice were able to lyse TEWETGQI-pulsed
splenocytes. Notably, the vaccination approach was able to prime
subdominant CTL targets from different regions of the construc-
tion as well (Nt-Cz domain, α-linker region) in a similar fashion.
This fact highlights the lack of immunodominance of Traspain
components and the efficacy of the formulation to increase the
breadth of the CTL response in vaccinated mice.
Traspain+c-di-AMP confers protection against different models of
T. cruzi murine infection
To analyze vaccine efficacy during the acute phase of infection, we
vaccinated female C3H mice with candidates plus c-di-AMP and
challenged them with highly virulent blood trypomastigotes of T.
cruzi RA strain, a combination of parasite-mouse strain that proved
suitable for this outcome of interest. All vaccinated mice were able
to control parasitemia, remarkably the highest reduction (6-fold)
was observed in Traspain vaccinated mice (mean area under the
parasitemia curve ±SEM, c-di-AMP: 330±20, Traspain+c-di-AMP:
54±9, Nt-Cz+ASP2+c-di-AMP: 102±22, ASP2+c-di-AMP: 95±24, Nt-Cz
+c-di-AMP: 91±12) (Fig. 6a). This fact also correlates with a
decrease in the weight loss (Fig. 6b). A 18% weight reduction was
observed in control mice after the first peak of parasitemia at
27dpi, whereas Nt-Cz+ASP2+c-di-AMP showed a 12% loss being
the immunized group with the worst performance. Similar
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protection levels were observed in Traspain, ASP2 or Nt-Cz+c-di-
AMP groups in terms of survival rate (Fig. 6c). However, Nt-Cz
+ASP2+c-di-AMP group failed to achieve equal protection. As a
whole, animals immunized with strategies different from Traspain
+c-di-AMP presented an intermediate performance.
Since T. cruzi has many ways to evade the immune response
and cause a chronic infection, it is essential to control parasite
replication during the first moment of its entrance. To assess this
matter, we determined the levels of parasitism at the site of
infection by employing CL-strain trypomastigotes expressing
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Fig. 2 Cellular immune response in vaccinated mice. Proliferative dose-response curve of spleen cells harvested 30 dpi from vaccinated mice
upon increasing concentrations of Traspain. Proliferation index (PI) (a). Secreted cytokines by ELISPOT assay at 30 dpi. Representative ELISPOT
plate showing IFN-γ producing colonies of spleen cells from indicated groups cultivated in the presence of 10 µg/ml of Traspain (b). Pooled-
splenocytes were re-stimulated with the indicated protein and mean number of spot forming units were determined for IFN-γ, IL-17, IL-2, or
IL-4 (c). Results are expressed as mean± SEM, n= 18 from 6 mice per group. One-way-ANOVA+Dunnett multiple comparison test. *p< 0.05,
**p< 0.01, ***p< 0.001 comparing with c-di-AMP group. Bars indicate significant difference (p< 0.05) between the indicated category of
stimulus and groups, two-way-ANOVA + Tukey’s multiple comparisons test. All results are representative of two independent experiments
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the tandem dimeric protein, tdTomato. As virulence of these
recombinant parasites is compromised, we employed male
C57BL/6 mice considering its higher susceptibility to T. cruzi
infection.11–13
As shown in Fig. 6d and e, the levels of fluorescence as a
surrogate marker of parasite replication in situ were reduced in
vaccinated mice in contrast with control animals. The early control
of parasite replication was associated with an increase in the
inflammation at the site of infection (Fig. 6f, g).
Vaccine effectiveness for the prevention of tissue damage
associated with chronic T. cruzi persistence
The progression of T. cruzi infection can lead to parasite-induced
damage in the target tissues. To assess whether vaccination
approaches were able to diminish tissue injury, we determined
the activity levels of serum enzymes associated with tissue
damage. Vaccinated animals were able to control tissue injury
during the chronic phase of the infection, showing less serum
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Unstimulated Traspain restimulated
Fig. 3 Antigen-specific CD4+ T cells generated during vaccination become activated and secrete cytokines upon re-encounter with the
cognate antigen. Spleen cells from individual mice were harvested 30 days after last dose and transient expression of CD154+ (CD40L) was
analyzed as an indicator of T cell activation upon antigen recall (a). Results are expressed as subtracted mean(restimulated mean—
unstimulated mean)± SEM. TNF-α and IFN-γ production by activated CD154+CD4+ T cells. Percentage of cytokine producing cells was
determined for IFN-γ+ (b), TNF-α+ (c), or TNF-α+IFN-γ+ cells (d). Flow cytometry plots for the indicated groups showing the gating strategy (e).
*p< 0.05, **p< 0.01, ***p< 0.001 comparing with c-di-AMP. One-way-ANOVA + Bonferroni multiple comparisons test (a) and two-way-ANOVA
+ Bonferroni multiple comparisons test (b–d), bar indicate p< 0.05 between groups, n= 4 per group. All results are representative of two
independent experiments
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and GOT compared to control-infected mice (Fig. 7a). To confirm
this data, we analyzed the presence of necrosis and chronic
inflammation in tissue sections from cardiac and skeletal
muscle as endpoints. As Fig. 7b shows, tissue sections of control
animals presented strong inflammatory infiltrates, and necrosis,
which was always associated with the presence of mononuclear
cells and higher levels of dystrophic calcification, all of which are
consistent with a severe tissue damage scenario. Comparison
between immunized groups revealed that all of them were able to
control heart damage. However, only mice immunized with
Traspain+c-di-AMP presented absence or a low level of skeletal
muscle damage as well as mononuclear infiltrate in contrast with


























































































































































Fig. 4 CD8+ T cell mediated immune responses of immunized mice. Priming of pathogen-specific CD8+ T cells by vaccination at 30 dpi (a).
Representative dot-plots for the indicated groups (b). Levels of circulating pathogen-specific CD8+ T cells in blood for Traspain+c-di-AMP
vaccinated and control mice (c) and representative zebra-plots of each group (d). Frequency of CD107α+ CD8+ T cells calculated upon antigen
re-stimulation of spleen cells from each group (d). Representative dot-plots of the indicated groups (e). Results are expressed as mean (a, c) or
subtracted mean (e)± SEM and are representative of two independent experiments, n= 4 per group. **p< 0.01, *p< 0.05, one-way-ANOVA +
Bonferroni multiple comparisons test (a, e). **p< 0.01 Mann–Whitney test (c)
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DISCUSSION
The rational design of Traspain as a trivalent inmunogen was
based on a series of criteria that guided us to select each of the
candidate to be incorporated in the chimeric gene. Thus, the Nt-Cz
was chosen based on its protective capacity and excluding the C-
terminal domain that distracts the immune response.14 It has a key
role as a source of B and T cell epitopes. Secondly, the sequence
from iTS was selected based on the α-helix structure that it adopts
in the native conformation. In Traspain, it works as a linker
between the N- and C-terminal domains acting as a molecular
ruler, a fact that may contribute to the independent folding of
each region.15 As we have shown it is also a source of
subdominant CD8+ T epitopes. Finally, the ASP2 central region
was incorporated based on its protective properties, its location
within the parasite membrane and expression pattern.16, 17 It
represents a potent target for the CTL response.18, 19 Noteworthy,
the B cell immune response triggered by the chimeric antigen
Traspain proved to be directed against both main domains in a
similar fashion and in lesser extend, against a 9-mer peptide of the
linker, as expected (Fig. 1).
Similar to previous reports,20 the profile of the immune
response triggered by c-di-AMP vaccination was associated with
a Th1/Th17 bias and was detected, although not in the same
magnitude, in all animals that received antigens+c-di-AMP. Thus,
we observed a 300-fold induction of IL-17 secreting cells in the
Traspain+c-di-AMP group compared with c-di-AMP alone and 200-
fold for the group that received Nt-Cz+ASP2 combined. The strong
production of this cytokine is associated on one hand to the
adjuvant per se and on the other to the mucosal route of
administration.21 IL-17 has been associated with protection during
the acute phase of infection, contributing to parasite control and
increasing survival of infected animals.22 Moreover, it has been
described as a mechanism by which regulatory neutrophils are
recruited to avoid the damage of an otherwise exaggerated Th1
response.23 Interestingly, it has been recently found that Th17
cells confer stronger protection than Th1 cells.24 This fact may
partially explain the better control of T. cruzi infection of Traspain
immunized mice compared to Nt-Cz+ASP2 vaccinated animals.
Flow cytometry data indicate that CD4+ T cells primed during
vaccination were able to secrete cytokines and transiently express
CD154 upon antigen recall ex-vivo. Interestingly, CD4+ T cells have
an essential role in the efficient priming of CD8+ responses. The
CD8+ T cells primed in the absence of T-cell-help are impaired in
terms of their ability to respond to a secondary re-encounter with
antigen, being compromised not only in the magnitude, but also
in the quality of the CTL response. Upregulation of CD154 by CD4+
T cells plays a pivotal role during DC-licensing, a key step for the
efficient priming of CD8+ T cells and optimal secondary CTL
responses.25, 26 This fact is also important in the context of T. cruzi
infection considering that helpless CD8+ T cells are of lower
intensity and unable to control T. cruzi acute infection.27 In this
scenario, it is reasonable to assume that vaccination with c-di-AMP
could be able to prime pathogen-specific CD8+ T cells. Indeed, we
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I
Fig. 5 Pathogen exposure triggers an expansion of antigen-specific memory CD8+ T cell subset. Blood of C57BL/6 mice immunized (30 dpi) or
immunized and challenged with 250,000 CL culture trypomastigotes (10 dpi) was analyzed for VNHRFTLV-specific CD8+ T cells by tetramer
staining (a). Percentage of pathogen-specific, vaccine unrelated CD8+ T cells (Tskb20) by tetramer staining in blood (I). Zebra-plots showing
VNHRFTLV-tetramer+ population on indicated groups (b). In vivo CTL assay (c). Spleen cells from C3H donor mice were loaded with peptides,
KEEASSAV (Nt-Cz domain), GELRIIKSV (α-linker-motive), and TEWETGQI (ASP2 domain), or unloaded. Cells were stained with CFSE, mixed in an
equal ratio, and i.v. injected to naïve (c-di-AMP), Traspain+c-di-AMP immunized or Traspain+c-di-AMP vaccinated and T. cruzi infected mice at
45 dpi (Vaccinated + T. cruzi). Representative density-plot showing percentage of CFSE populations in the indicated groups. Crosses represent
the median value of each dimension in each gate (d). pep 1: KEEASSAV, pep 2: GELRIIKSV, pep 3: TEWETGQI. Results are expressed as mean ±
SEM, and represent at least three independent experiments, n= 6 per group (a, b) and n= 3 per group (c, d), ***p< 0.001, **p< 0.01, *p< 0.05.
1way-ANOVA + Tukey’s multiple comparisons test (a)
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vaccinated mice (Fig. 4a–d). Furthermore, these cells were able to
degranulate upon antigen re-stimulation. Interestingly, they
showed re-expansion capacity upon pathogen exposure, increas-
ing not only in frequency (Fig. 5a) but also in functionality as
determined by the ability to lyse peptide loaded target cells
(Fig. 5c). Traspain vaccination was able to prime functional CD8
T cells directed against both dominant and subdominant (Nt-Cz
and α-linker region) CTL epitopes. Altogether, these results
highlight the ability of c-di-AMP to trigger cross-presentation of
proteins as well as in vivo cross priming of specific CTL.
Moreover, a series of proof of concept studies were carried out
challenging vaccinated animals with T. cruzi from different strains.
Antigens+c-di-AMP were able to control acute infection in terms
of parasitemia, weight loss, and survival (Fig. 6). Interestingly,
during the chronic phase of the infection, vaccinated mice
showed a decreased serum activity of tissue damage-associated
enzymes. More importantly, Traspain+c-di-AMP vaccinated mice
showed the lowest level of mononuclear infiltrate in skeletal
muscle, compared with others groups (Fig. 7). These animals
were also able to control parasite replication during the first
days of infection, a fact that was associated with an earlier
pro-inflammatory response at the site of infection. Further
experiments are necessary to determine the etiology of the
inflammatory process and the involvement of circulating or
resident memory T cells.28, 29 As the outcome of interest for an
anti-T. cruzi vaccine should be focus on the reduction of chronic
inflammation-associated damage, Traspain+c-di-AMP proved to
be the best strategy assayed in terms of vaccine effectiveness con-
ferring protection against diferent strains of parasites and mice
independently of the sex bias of T. cruzi infection.
Considering that antigen load is an essential factor for the
priming of T cell responses,30 it is clear that Traspain allows a
lower amounts of antigen (10 µg of Transpain contains a lower
amount of molecules than 10 µg of each antigen alone) to be
presented more efficiently when we compared the triggered
immune response to that obtained with each antigen alone.
Moreover, when the molar dose of each antigen was reduced to
that of Traspain in Nt-Cz+ASP2+c-di-AMP group, the immune
respose although from the same quality was not as robust and
failed to achieve similar levels of protection (Fig. 6c). In addition,
since the chimeric molecule presents higher MW, pI, number and
distribution of charged residues, the physicochemical differences
of each formulation could influence self-assembly processes
including particle or aggregates formation increasing the prob-
ability of protein uptake and antigen processing. Electron
microscopy, analitycal SEC and DLS assays should reveal this
issues in futher studies. Furthermore, we could not discard an
scenario, where DC competition for the antigen uptake and
processing takes place as well as the possibility that one antigen
may interfere with the other during steps of T cell priming in Nt-Cz
+ASP2+c-di-AMP group.
      c-di-AMP Traspain+c-di-AMP
4dpi
9dpi
a                                                                       d
b                                                                        e










































































































































Fig. 6 Vaccine efficacy during the acute phase of T. cruzi infection. Vaccinated C3H mice were challenged 30 days after the last dose with a
lethal intraperitoneal (i.p.) dose of T. cruzi RA strain trypomastigotes and analyzed for: parasitemia (a), body weight loss (b) and survival (c), n=
6 per group, **p< 0.01, Log-Rank Test, ns: not significant vs. control. Footpad challenge of the indicated groups with trypomastigotes of the
CL-tdTomato strain. Mean fluorescence intensity of feet determined by in-vivo imaging, between 1 and 10 dpi (d). Representative images from
4 to 9 dpi showing the control of parasite replication at the site of infection in vaccinated animals (e). Area under the curve of fluorescence per
site of infection (n= 12) (f). Footpad swelling at 6 dpi (g). Footpad diameter was measured using a caliper. Data show the mean difference
between day 0 and 6 per mouse. **P< 0.01, ***p< 0.001, Mann–Whitney test. The results are representative of at least three independent
experiments
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This is the first report to present a chimeric molecule containing
the Nt-Cz and ASP-2, both main T. cruzi vaccine candidates, which
showed protection during the whole course of the infection.
Despite the immune response demonstrated towards the linker
motive, its protective quality alone remains to be proved in further
studies. The intrinsic complexity of T. cruzi, with more than 12,000
protein coding genes per haploid genome, six discrete type units,
and the presence of protein superfamilies with repetitive and
polymorphic variants31, 32 highlights the difficulty in finding only
one target that confers acceptable levels of protection against the
Group
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Traspain+c-di-AMP
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Skeletal muscle                    -/+                        -/+
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infection. Designing an anti-T. cruzi vaccine is challenging not only
because of these facts but also due to the kind of immune
response required in order to achieve protection. Thus, cell-
mediated immunity, particularly CD8+ T cells, plays a crucial role in
controlling parasite infection.2 Considering this scenario, we
believe that a multicomponent vaccine is appropriate in order
to increase the breadth of the immune response triggered by
vaccination. Our results highlight the importance of designing
chimeric molecules in multicomponent vaccines a fact that must
be considered not only to reduce production costs but also to
seek for an improvement in the magnitude and quality of the
immune response elicited by each component.
Prompt control of T. cruzi infection might require the
identification of early antigens such as flagellar proteins33 and
the incorporation to new chimeric molecules as Traspain
represent an attractive area of research for the development of
novel anti-T. cruzi vaccines.
MATERIALS AND METHODS
Mice and parasites
Female C3H/HeN (H-2k) mice 6–8-weeks-old were kept at the
animal facility of the Helmholtz Center for Infection Research under
specific pathogen-free (spf) conditions. C57BL/6 (H-2b) mice were
maintained in the University of Georgia animal facility under spf
conditions. Animal experiments were approved by the ethical board
and conducted in accordance to the regulations of Lower Saxony No.
09.4250204105/07, Germany, UBA-CONICET, Argentina and IACUC,
UGA, USA. T. cruzi bloodstream trypomastigotes of the RA and the
recombinant Tulahuen strain expressing β-galactosidase34 were isolated
from infected mice. Tissue culture trypomastigotes of the CL strain of T.
cruzi wild-type or expressing tdTomato were obtained from passage
through Vero cells.35
Recombinant proteins
The Nt-terminal domain of Cz (Nt-Cz) was produced as previously
described.14 The ASP2 transcript was obtained from T. cruzi amastigote
cDNA from the RA strain as reported.36 The central region of ASP2
protein (residues 261–570), herein referred to as ASP2, was amplified
employing gene-specific primers and cloned in a pET23a vector. For
Traspain construction, sequential PCR was done to build the alpha helix
linker incorporating nucleotides 1205–1281 from CL-Brener iTS
(XM_811430.1) to Nt-Cz. Splicing by overlap extension PCR37, 38 was
performed in order to obtain the hybrid gene with ASP2. Cloning was
done in a pET23a vector. Gene sequencing was performed to confirm the
chimeric gene. Traspain and ASP2 were expressed in E. coli BL21 (DE3) as
inclusion bodies, purified under denaturing conditions by IMAC and
in vitro refolded by dialysis method. Purity levels were determined by SDS-
PAGE and presence of endotoxin was assessed by LPS-Detection Kit
(invivogen).
Immunizations and challenge
Inbred female C3H/HeN mice 6–8-weeks-old were immunized by the
intranasal route with three doses every 15 days as follows: (I) c-di-AMP, (II)
Traspain, (III) Traspain+c-di-AMP, (IV) Nt-Cz+ASP2+c-di-AMP, (V) ASP2+c-di-
AMP, and (VI) Nt-Cz+c-di-AMP. Each group received 10 µg of each
component, with the exception of group IV that received equal molar
amounts of each antigen. For analysis of the acute phase, 15–30 days
after the last dose, mice were challenged with 103 T. cruzi RA strain
blood trypomastigotes by the intraperitoneal route. For sublethal
assays 102 parasites were administered. Alternatively, male C57BL/6
were immunized following the same schedule and challenged in the hind
footpads with 2.5 × 105 T. cruzi tdTomato trypomastigotes.
ELISA titration of antigen-specific IgG Abs
Protein-specific antibody titers were determined as previously
described39 by ELISA using plates coated with 0.2 μg of Traspain, Nt-Cz,
or ASP2 per well. Peroxidase conjugated goat immunoglobulins to
mouse immunoglobulin (Ig) G were used as the secondary antibody.
Plates were developed by adding o-phenylenediamine/H2O2. For peptide-
ELISA, plates were coated with 10 µM of GELRIIKSV in carbonate buffer pH
9.6 ON, washed and blocked, sera was incubated ON. Biotin conjugated
goat immunoglobulins to mouse IgG plus streptavidin-peroxidase
were used as the secondary antibody. Plates were developed by adding
TMB/H2O2.
Neutralization assay
Raw cells (5 × 103 cells/well) were infected with blood trypomastigotes
expressing β-galactosidase at a MOI of 10:1 for 24 h at 37 °C. Trypomas-
tigotes were pre-incubated in triplicate with diluted serum (1/10) from
mice belonging to each immunization group. After overnight incubation
cells were washed and incubated for 5 days. CPRG was added to determine
the levels of parasites as previously described.40
Proliferation assay
Spleen cells (5 × 105 cells/well) of each vaccination group were incubated
in quadruplicates for 96 h in the presence of different concentrations of
Traspain (1, 10, 20, and 40 µg/ml) and proceeded as previously reported.20
Results were expressed as the ratio of mean values from stimulated and
non-stimulated samples, proliferation index (PI).
ELISPOT assays
Spleen cells (4 × 105/2 × 105 cells/well) were incubated for 24 h (IFN-γ) or
48 h (IL-2, IL-17, and IL-4), in the absence or presence of 10 µg/ml of either
Traspain or ASP2 or Nt-Cz for ELISPOT assays (BD Pharmingen, USA). After
incubation, cells were removed and the plates were processed according
to the manufacturer’s instructions. Colored spots were counted with an
ELISPOT reader (CTL S5 Micro Analyzer) and analyzed using ImmunoSpot
image analyzer software v3.2 (CTL Europe GmbH, Germany).
Intracellular cytokine staining
Isolated splenocytes were stimulated overnight with 10 µg/ml of Traspain
in the presence of anti-CD154-PE and anti-CD107 PE-Cy7. Brefeldin A plus
monensin was added to cultures during the last 6 h of incubation. Surface
staining was performed with anti-CD3e-V500, anti-CD4-APC-H7 (BD), and
anti-CD8α-Brilliant-Violet-650 (BioLegend). Cells were fixed with PFA 2%,
permeabilized in 0.5% saponin, and stained using anti-IFN-γ-Brilliant-Violet-
711 (BioLegend) and anti-TNF-α-eFluor450 (eBioscience) in accordance
with the manufacturer’s instructions.
MHC class I multimer staining
To detect antigen-specific T cells, spleen or blood cells were first labeled
with H2Kk-TEWETGQI dextramer-APC (Immudex) and then with anti-CD3e
V500, anti-CD4-APC-H7 (BD), and anti-CD8α-Brilliant Violet V650 (BioLe-
gend) according to the manufacturer’s instructions. Alternatively, either
H2Kb-VNHRFTLV-APC or H2Kb-ANYKFTLV-APC (Tskb20) tetramer (NIH
Tetramer Core Facility, Emory University, USA) were employed for C57BL/
6 mice.
Fig. 7 Vaccine effectiveness for the prevention of tissue damage. Serum activity of cardiomyopathy-associated enzymes from immunized and
infected mice. Creatinine kinase (CK), creatinine kinase MB isoform (CK-MB), lactate dehydrogenase (LDH, U/I ×10), and glutamate
oxaloacetate transaminase (GOT) (a). Results are expressed as mean± SEM. *p< 0.05, **p< 0.01, one-way-ANOVA Kruskal-Wallis test + Dunn’s
multiple comparisons test. Histopathological analysis of T. cruzi-target organs during the chronic phase of infection. Representative tissue
sections (H&E stained) for the indicated groups (b). Magnification level: 100×. Insets: 400×. Table shows Inflammation score semi-quantitatively
evaluated for each group (-, absence of inflammation; number of crosses indicate degree of inflammation). Solid arrows point to mononuclear
cell infiltrates. Dashed arrow points to a nerve associated with mononuclear cell infiltrates. Results are representative of two independent
experiments
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In vivo cytotoxicity assay
Splenocytes collected from naïve C3H/HeN mice were incubated with 5 μM
of peptides, pep1: TEWETGQI (ASP2), pep2: KEEASSAV (Nt-Cz), and pep3:
GELRIIKSV (α-linker-iTS) or no peptide for 30min at 37 °C and 30min at 4 °
C, washed, and then labeled with 2.5, 5, 10, and 0.5 μM of CFSE
(CellTrace™ CFSE Cell Proliferation Kit), respectively. Cells were washed,
combined, and transferred (4 × 107 total cells) intravenously to syngenic
naïve (c-di-AMP), traspain+c-di-AMP immunized, and T. cruzi infected mice
at 45 dpi. Sixteen hours after transfer, spleens were harvested and
analyzed by flow-cytometry. The percentage of specific lysis was calculated
as follows: % Specific lysis = 1−[(%CFSEpep/%CFSEunloaded) Immunized/(%
CFSEpep /%CFSEunloaded)naïve] * 100
Assessment of vaccine efficacy
Parasitemia was monitored by counting peripheral parasites every 2 days
as previously described.40 In tdTomato T. cruzi infection the fluorescent
intensity was measured using a whole animal imaging system (Maestro2 In
Vivo Imaging System CRi, USA) as a surrogate of parasite load.35 Muscle
injury was evaluated through the determination of a panel of myopathy-
linked enzyme markers as previously described.39 The histological features
of heart and skeletal muscles were also investigated. A blind histological
test was performed as previously described.41
Statistical analysis
Statistical analysis was carried out with Graphpad Prism 6.0 software (San
Diego, CA, USA) using one-way ANOVA, n = 6 animals/group unless
otherwise specified in figure legends, p-values <0.05 were considered
significant.
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